James Healy has bought stock on 11 days since Jul 2019

James Healy, MD, PhD, is a corporate insider and director at BioAge Labs, Inc. (BIOA), where he serves on the board and is a member of the Compensation and Nominating & Corporate Governance Committees.( His recent Form 4 filing with the U.S. Securities and Exchange Commission reflects a grant of 22,000 stock options in BioAge Labs, structured as director compensation and vesting by the next annual stockholder meeting or the one-year anniversary of the grant date.( Healy previously served as Chair of BioAge’s Board of Directors and continues as a board member.(

Professionally, Healy is the Managing Partner of Sofinnova Investments, a life sciences-focused venture capital firm, and has over two decades of experience funding innovative biotechnology companies.( Over his twenty-year career at Sofinnova, he has invested in more than thirty companies, with over twenty going public and multiple portfolio companies being acquired, and has been involved in financing companies that have brought numerous FDA- and EMA-approved therapies to market.( Healy sits or has sat on the boards of several biopharmaceutical and therapeutics companies, including ArriVent, BioAge, Rapport, Seaport, and previously Karuna and CinCor, among others.( He holds a B.A. in Molecular Biology and a B.A. in Scandinavian Studies from the University of California, Berkeley, and earned his MD and PhD in Immunology through the NIH-sponsored Medical Scientist Training Program at Stanford University.(

Written by Perplexity from public sources.